Table 1.
Rate ratio | 95% CI | Relative weight | Homogeneity | |
---|---|---|---|---|
ACEIs versus ARBs | ||||
Bloom19 | 1.19 | 1.03–1.32 | 0.26 | |
Elliott et al23 | 1.14 | 1.09–1.20 | 0.28 | |
Wogen et al33 | 1.45 | 1.43–1.47 | 0.29 | |
Degli Esposti et al36 | 1.58 | 1.12–2.08 | 0.16 | |
Pooled | 1.30 | 1.10–1.54 | 1.00 | 0.000 |
CCBs versus ARBs | ||||
Sung et al38 | 1.10 | 1.09–1.11 | 0.29 | |
Elliott et al23 | 1.32 | 1.26–1.39 | 0.28 | |
Wogen et al33 | 1.33 | 1.31–1.35 | 0.29 | |
Degli Esposti et al36 | 2.07 | 1.57–2.73 | 0.14 | |
Pooled | 1.33 | 1.16–1.54 | 1.00 | 0.000 |
Diuretics versus ACEIs | ||||
Elliott et al23 | 1.53 | 1.47–1.61 | 0.14 | |
Taira et al25 | 1.49 | 1.40–1.60 | 0.14 | |
Van Wijk et al26 | 1.52 | 1.46–1.57 | 0.14 | |
Van Wijk et al26 | 1.32 | 1.28–1.36 | 0.15 | |
Van Wijk et al26 | 1.38 | 1.33–1.43 | 0.14 | |
Friedman et al30 | 1.17 | 1.10–1.25 | 0.14 | |
Sung et al38 | 1.16 | 1.14–1.17 | 0.15 | |
Pooled | 1.36 | 1.22–1.51 | 1.00 | 0.000 |
Diuretics versus ARBs | ||||
Degli Esposti et al36 | 2.62 | 1.99–3.46 | 0.10 | |
Taira et al25 | 1.61 | 1.50–1.70 | 0.15 | |
Van Wijk et al26 | 1.50 | 1.42–1.57 | 0.15 | |
Van Wijk et al26 | 1.45 | 1.31–1.56 | 0.15 | |
Van Wijk et al26 | 1.52 | 1.47–1.56 | 0.15 | |
Friedman et al30 | 1.07 | 0.93–1.22 | 0.14 | |
Sung et al38 | 1.16 | 1.14–1.17 | 0.15 | |
Pooled | 1.47 | 1.27–1.70 | 1.00 | 0.000 |
Diuretics versus CCBs | ||||
Friedman et al30 | 1.08 | 0.99–1.19 | 0.19 | |
Taira et al25 | 2.01 | 1.90–2.20 | 0.20 | |
Van Wijk et al26 | 1.46 | 1.35–1.53 | 0.20 | |
Van Wijk et al26 | 1.15 | 1.06–1.22 | 0.20 | |
Van Wijk et al26 | 1.23 | 1.16–1.29 | 0.20 | |
Pooled | 1.35 | 1.14–1.60 | 1.00 | 0.000 |
Depression versus no depression | ||||
Rasmussen et al16 | 2.13 | 1.44–3.14 | 0.02 | |
Rasmussen et al16 | 1.81 | 1.07–3.07 | 0.01 | |
Perreault et al24 | 0.93 | 0.85–1.02 | 0.14 | |
Van Wijk et al26 | 1.10 | 0.99–1.14 | 0.19 | |
Van Wijk et al26 | 1.14 | 1.05–1.25 | 0.14 | |
Van Wijk et al26 | 1.03 | 0.94–1.12 | 0.15 | |
Siegel et al29 | 1.16 | 1.14–1.18 | 0.20 | |
Evans et al39 | 1.17 | 1.09–1.26 | 0.16 | |
Pooled | 1.11 | 1.05–1.18 | 1.00 | 0.000 |
Low income versus higher | ||||
Rasmussen et al16 | 1.05 | 0.91–1.11 | 0.09 | |
Rasmussen et al16 | 1.07 | 0.94–1.23 | 0.06 | |
Perreault et al24 | 1.34 | 1.26–1.42 | 0.09 | |
Van Wijk et al26 | 0.94 | 0.86–1.02 | 0.08 | |
Van Wijk et al26 | 1.19 | 1.15–1.23 | 0.09 | |
Van Wijk et al26 | 1.05 | 1.01–1.10 | 0.09 | |
Gogovor et al28 | 1.02 | 0.83–1.26 | 0.04 | |
Gogovor et al28 | 1.26 | 1.11–1.42 | 0.06 | |
Friedman et al30 | 1.10 | 1.08–1.12 | 0.10 | |
Corrao et al31 | 1.02 | 0.98–1.05 | 0.09 | |
Wong et al37 | 1.22 | 1.15–1.29 | 0.09 | |
Evans et al39 | 1.60 | 1.31–1.96 | 0.04 | |
Rasmussen et al40 | 0.98 | 0.90–1.14 | 0.09 | |
Pooled | 1.12 | 1.06–1.18 | 1.00 | 0.000 |
Diabetics versus nondiabetics | ||||
Rasmussen et al16 | 0.98 | 0.68–1.22 | 0.03 | |
Rasmussen et al16 | 1.16 | 0.85–1.38 | 0.02 | |
Setoguchi et al17 | 1.03 | 1.00–1.06 | 0.12 | |
Setoguchi et al17 | 1.03 | 0.99–1.06 | 0.11 | |
Degli Esposti et al20 | 0.50 | 0.17–0.76 | 0.04 | |
Perreault et al24 | 1.14 | 1.06–1.21 | 0.09 | |
Taira et al25 | 1.13 | 1.10–1.20 | 0.12 | |
Van Wijk et al26 | 1.01 | 0.92–1.09 | 0.09 | |
Van Wijk et al26 | 1.03 | 1.00–1.14 | 0.09 | |
Van Wijk et al26 | 1.17 | 1.10–1.24 | 0.09 | |
Gogovor et al28 | 1.11 | 0.92–1.27 | 0.04 | |
Gogovor et al28 | 1.19 | 1.07–1.29 | 0.06 | |
Siegel et al29 | 1.02 | 0.99–1.04 | 0.12 | |
Pooled | 1.07 | 1.02–1.11 | 1.00 | 0.000 |
Black versus White | ||||
Setoguchi et al17 | 1.23 | 1.19–1.27 | 0.15 | |
Setoguchi et al17 | 1.09 | 1.06–1.13 | 0.15 | |
Yang et al21 | 1.38 | 1.36–1.39 | 0.15 | |
Shaya et al22 | 1.55 | 1.30–1.71 | 0.13 | |
Van Wijk et al26 | 1.42 | 1.19–1.66 | 0.11 | |
Siegel et al29 | 1.08 | 1.07–1.09 | 0.15 | |
Yang et al21 | 1.28 | 1.27–1.30 | 0.15 | |
Pooled | 1.27 | 1.14–1.42 | 1.00 | 0.000 |
Abbreviations: CI, confidence interval; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers.